Diagnostic Products. 6.2.1 With respect to Diagnostic Antibody Products, Dyax shall pay to CAT the following payments upon achievement by Dyax or a Dyax Sublicensee (or its sublicensee) of the milestones set out below. For the avoidance of doubt the milestone payments shall be payable in respect of the first Diagnostic Antibody Product to achieve the relevant milestone: First filing for Marketing Authorisation in one Major Market country US $ Marketing Authorisation granted in each Major Market Country US $
Diagnostic Products. Notwithstanding anything to the contrary contained herein, [***].
Diagnostic Products. 15 6. PAYMENTS...............................................................16 7.
Diagnostic Products. In addition, Licensee shall pay Harvard the following milestone payments with respect to each Licensed Product being commercialized for the diagnosis of [**] (a “Diagnostic Product”) to reach the relevant milestone, regardless of whether such milestone is achieved by Licensee or a Sublicensee:
Diagnostic Products. If CELGENE or any of its Affiliates or sublicensees Commercializes a Diagnostic Product under the license granted to CELGENE pursuant to Section 5.1.2, the Parties shall negotiate in good faith a reasonable royalty to be paid by CELGENE to EPIZYME, taking into account the facts and circumstances at such time, including profitability of such Diagnostic Product.
Diagnostic Products. Notwithstanding anything to the contrary contained herein, [***]. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Diagnostic Products. In the event that any Diagnostic Product (as -------------------- defined in Section 1.30(b)), either in the Field or outside the Field, is developed by BMS, its Affiliates, Sublicensees or other designees, the parties shall negotiate in good faith the additional terms thereof, including applicable milestone payments and announcements, and royalties thereon. *** Information omitted and filed separately with the Commission under Rule 24b-2.
Diagnostic Products. If LILLY wishes to develop and commercialize a diagnostic product in the Field utilizing a lead Ribozyme Product in active development as specified in the R&D Plan or that is commercially being used by LILLY under this Agreement, RPI shall grant to LILLY the right to develop and commercialize such diagnostic product on commercially reasonable terms and conditions applicable in the diagnostic market, based upon similar diagnostic products, as negotiated in good faith between the Parties and which shall not exceed the royalties set forth. If the Parties are unable to reach an agreement on the terms for commercialization of such diagnostic products, then RPI shall retain the rights to develop and commercialize such products independently or with one or more Third Party.
Diagnostic Products. The effects of termination with respect to Diagnostic Products shall be the same as set forth with respect to Antibody Products in Section 13.5.4(a)(2) and (5), [***] and the rights described in Section 13.5.4(a)(3) and (4) shall be deemed to extend to Diagnostic Products [***].
Diagnostic Products. If the termination is by Merck under Section 13.3, then the effects of termination with respect to Diagnostic Products shall be the same as set forth with respect to Antibody Products in Section 13.5.4(b), including (1), (2) and (3), provided that the maximum royalty shall not exceeded [***] the royalties in Section 6.7.1(b).
